Breast Cancer Active Surveillance, Alternative Option, Aspirin Included
Breast Cancer Active Surveillance, Alternative Option, Aspirin Included
Experimental, clinical, and epidemiological studies have all demonstrated the strong
 association between chronic inflammation and cancer, and many studies have correlated the
 prolonged presence of the inflammatory milieu with an increased risk for developing
 cancer.(1) Although the potential mechanism for aspirin preventing breast cancer is not
 known, possible pathways may involve platelets, inflammation, cyclooxygenase (COX) 2,
 hormones, or PI3 kinase. (2).

 In actual clinical practice there exist clear guidelines for the use of aspirin in colorectal
 cancer but no such guidelines exist for the use of aspirin in breast cancer patients.

 In the Unit´s proper experience, in patients under active surveillance and metastatic ones
 some present very good responses both in the neoadjuvant and in the metastatic setting but
 investigators intend to provide evidence and not just the experience. This study patients are
 proposed to combine their standard treatment with aspirin.
Breast cancer patients with diagnosis of Ductal or Lobular Invasive Carcinoma or CDis that
 refuse to underwent surgery or are not qualified for, and independently of age or of their
 actual staging, are going to be allocated, randomly and in double masked way to one of two
 arms:

 Arm 1: standard Unit´s protocol + placebo Arm 2: standard Unit´s protocol + aspirin
Inclusion Criteria:

 Every adult (above 18) y.o.patient with histologic diagnosis of Breast Cancer that refuse
 or is not suitable for surgical treatment, or with metastatic disease, remaining this way
 in an "active surveillance"

 Exclusion Criteria:

 Allergy or toxicity to aspirin